Key facts
- Nocion Therapeutics’s last known valuation is $112.0M (Aug 2021).
- It has raised $153.0M across 3 recorded rounds; the latest was Early Stage VC ($23.0M) in Dec 2025.
- Notable investors include RA Capital Management, F-Prime Capital, Eight Roads, Alexandria Venture Investments, Canaan Partners — 16 tracked in total.
- Nocion Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently Mar 2026 ($23.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Nocion Therapeutics
Funding rounds
3 roundsAbout Nocion Therapeutics
Developer of a small molecule charged sodium channel designed to treat the conditions arising from neurogenic inflammation. The company creates notions that target activated sensory neurons and enter activated nociceptors via large-pore channels on these neurons, enabling patients to gain relief through the treatment of serious conditions, including cough, itch, pain, and inflammation.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2017
- Employees
- 17
- Website
- nociontx.com/
- Ownership
- Privately Held (backing)
Nocion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nocion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nocion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.